Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Scott E. Eggener

Urology
UChicago Medicine
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
UChicago Medicine
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Eggener is an Urologist in Chicago, Illinois. Dr. Eggener is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Testicular Cancer, Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Eggener is currently accepting new patients.

His clinical research consists of co-authoring 277 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in IL
Hospital Affiliations
Ingalls Memorial Hospital
Northwest Community Hospital 1
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Adventist Hinsdale Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637
Call: 773-702-1000
Other Locations
THE UNIVERSITY OF CHICAGO
1101 S Canal St, Suite 201, Chicago, IL 60607
Call: 877-336-5667
THE UNIVERSITY OF CHICAGO
355 E Grand Ave, Chicago, IL 60611
Call: 888-824-0200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Antiandrogen therapy, Docetaxel
Study Phase: Phase 2
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2025
Intervention Type: Device, Other
Study Phase: Not Applicable
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 2/Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
View 6 Less Clinical Trials

277 Total Publications

A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: Erratum.
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: Erratum.
Journal: The Journal of urology
Published: July 08, 2025
View All 277 Publications
Similar Doctors
Kent T. Perry
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kent T. Perry
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kent T. Perry
Urology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
312-695-8146
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kent Perry is an Urologist in Chicago, Illinois. Dr. Perry has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Ureterocele, Prostate Cancer, Nephrectomy, and Ureteroscopy.

Gopal N. Gupta
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gopal N. Gupta
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gopal N. Gupta
Urology

Loyola University Medical Center

715 W N Ave, 
Melrose Park, IL 
 (15.0 miles away)
708-450-4554
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Gopal Gupta is an Urologist in Melrose Park, Illinois. Dr. Gupta is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Prostate Cancer, Nephrectomy, and Cystectomy. Dr. Gupta is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Marcus L. Quek
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Marcus L. Quek
Urology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (12.9 miles away)
708-216-9000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marcus Quek is an Urologist in Maywood, Illinois. Dr. Quek is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Cystectomy. Dr. Quek is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eggener's expertise for a condition
ConditionClose
  • Elite
  • Familial Prostate Cancer
    Dr. Eggener is
    Elite
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Prostate Cancer
    Dr. Eggener is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Prostatectomy
    Dr. Eggener is
    Elite
    . Learn about Prostatectomy.
    See more Prostatectomy experts
  • Testicular Cancer
    Dr. Eggener is
    Elite
    . Learn about Testicular Cancer.
    See more Testicular Cancer experts
  • Distinguished
  • Chromophobe Renal Cell Carcinoma
    Dr. Eggener is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Eggener is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Nephrectomy
    Dr. Eggener is
    Distinguished
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Orchiectomy
    Dr. Eggener is
    Distinguished
    . Learn about Orchiectomy.
    See more Orchiectomy experts
  • Renal Cell Carcinoma (RCC)
    Dr. Eggener is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Teratoma of the Mediastinum
    Dr. Eggener is
    Distinguished
    . Learn about Teratoma of the Mediastinum.
    See more Teratoma of the Mediastinum experts
View All 8 Distinguished Conditions
  • Advanced
  • Empyema
    Dr. Eggener is
    Advanced
    . Learn about Empyema.
    See more Empyema experts
  • Familial Wilms Tumor 2
    Dr. Eggener is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Hydronephrosis
    Dr. Eggener is
    Advanced
    . Learn about Hydronephrosis.
    See more Hydronephrosis experts
  • Reconstructive Urology Surgery
    Dr. Eggener is
    Advanced
    . Learn about Reconstructive Urology Surgery.
    See more Reconstructive Urology Surgery experts
  • Wilms Tumor
    Dr. Eggener is
    Advanced
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • Experienced
  • Bacterial Prostatitis
    Dr. Eggener is
    Experienced
    . Learn about Bacterial Prostatitis.
    See more Bacterial Prostatitis experts
  • Bladder Cancer
    Dr. Eggener is
    Experienced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Choriocarcinoma
    Dr. Eggener is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Endoscopy
    Dr. Eggener is
    Experienced
    . Learn about Endoscopy.
    See more Endoscopy experts
  • Enlarged Prostate (BPH)
    Dr. Eggener is
    Experienced
    . Learn about Enlarged Prostate (BPH).
    See more Enlarged Prostate (BPH) experts
  • Hydrocele
    Dr. Eggener is
    Experienced
    . Learn about Hydrocele.
    See more Hydrocele experts
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved